[Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration?].
Martín de Francisco
A L
AL
D002614:Chelating Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000191:economics* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications; D010710:Phosphates / Q000378:metabolism; D017410:Practice Guidelines as Topic
D002614:Chelating Agents; D010710:Phosphates